What is the human dosage of acepromazine

L-Polamivet® 2.5 / 0.125 mg / ml

composition

1 ml solution for injection contains:

Active ingredient (s):
Levomethadone Hydrochloride 2,500 mg
Fenpipramide hydrochloride 0.125 mg

Other ingredients, knowledge of which is necessary for the appropriate administration of the product:
Methyl 4-hydroxybenzoate 1,000 mg

Clear, colorless solution

Application areas)

Horse:
For neuroleptanalgesia in combination with xylazine.

Dog:
For anesthesia premedication and neuroleptanalgesia in combination with xylazine or acepromazine.

Contraindications

- epileptoid and strychnine-related seizures, tetanus
- Use with increased intracranial pressure
- Due to the respiratory depression, careful use during inhalation anesthesia.

Do not use on mares whose milk is intended for human consumption.

Side effects

- respiratory depression
- drop in body temperature
- tendency to vomit
- acoustic excitability
- During the waking up phase, the dog may make noises (howling, whining)
- The longer effect of fenpipramide leads to tachycardia and falling blood pressure when the opiate effect wears off after a subsequent injection.

If you notice any side effects in your animal, especially those not listed in the package insert, please inform your veterinarian or pharmacist.

Dosage for each species, type and duration of application

For slow intravenous and intramuscular use.

Horse:
Neuroleptanalgesia in combination with xylazine:
0.05-0.075 mg levomethadone hydrochloride and 0.0025-0.0038 mg fenpipramide hydrochloride with
0.4-0.6 mg xylazine per kg body weightintravenous, corresponding

Per100 kg body weight
2-3 ml L-Polamivet and 40-60 mg xylazineintravenous

Dog:
Anesthesia premedication or neuroleptanalgesia in combination with acepromazine:
0.25-1 mg levomethadone hydrochloride and 0.013-0.05 mg fenpipramide hydrochloride with
0.02-0.3 mg acepromazine per kg body weightintravenous orintramuscular, corresponding

Per10 kg body weight
1-4 ml L-Polamivet with 0.2-3 mg acepromazineintravenous orintramuscular

Neuroleptanalgesia in combination with xylazine:
0.375-0.5 mg levomethadone hydrochloride and 0.019-0.025 mg fenpipramide hydrochloride with
2 mg xylazine per kg body weightintramuscular, corresponding

Per10 kg body weight
1.5-2 ml L-Polamivet and 20 mg xylazineintramuscular

A lower dosage is indicated
a) in the case of a poor preoperative condition of the patient such as B. liver or kidney damage,
b) when the desired operating depth is reached during the injection.

The indicated dosages are non-binding guide values, which have to be adjusted according to the individual requirements of the individual animal and its individual reaction.
Particularly when combining L-Polamivet with neuroleptics, sedatives and narcotics, appropriate interactions must be observed and the dosages adjusted.

Instructions for correct use

It is recommended that dogs be given L-Polamivet on an empty stomach.

The dogs under the influence of L-Polamivet are to be protected from strong acoustic stimuli, cold and wet, as far as possible, covered with warm covers and placed on a suitable surface in a warm place.

waiting period

Horse:
Edible tissues 3 days

Do not use on mares whose milk is intended for human consumption.

Special storage instructions

Keep medicines out of the reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use the medicine after the expiry date stated on the container and outer packaging.
Shelf life after first opening the immediate packaging: 28 days
After this period has expired, any remnants of the drug remaining in the container must be discarded.

Special warnings

Special warnings for each target species:
Antagonist (in dogs)
The sleep after L-Polamivet, which sometimes lasts up to several hours, is often welcomed as a welcome rest. In special cases, however, it can also be undesirable.

To end L-Polamivet sleep quickly, naloxone hydrochloride can be used. The dosage and method of administration of naloxone hydrochloride can be found in the corresponding information for use. It should be noted that the antagonization of the levomethadone component in L-Polamivet can lead to an overhang due to fenpipramide hydrochloride, which can lead to massive tachycardia.

A postoperative circulatory control is recommended for older and circulatory-unstable animals.

Special precautions for use in animals:
It is recommended that dogs be given L-Polamivet on an empty stomach.
Inject L-Polamivet intravenously very slowly.
Restlessness and howling of the animals during the injection are signs of underdosing, so keep injecting!
On the other hand, convulsive jerks indicate an individual overdose, so stop the injection!
For dogs, the total amount including any additional dosing should not exceed 25 ml.
The dogs under the influence of L-Polamivet are to be protected from strong acoustic stimuli, cold and wet, as far as possible, covered with warm covers and placed on a suitable surface in a warm place.

Special precautions for the user:
L-Polamivet is subject to the regulations governing narcotics.

Use during pregnancy, lactation or lay:
Levomethadone crosses the placental barrier and can cause respiratory depression in newborns.

Interactions with other drugs and other forms of interaction:
The effect of levomethadone is antagonized by naloxone.
The central attenuation is increased by sedative hypnotics, barbiturates and phenothiazines.

Overdose (symptoms, emergency procedures and antidotes), if necessary:
Overdosing can lead to respiratory failure, cyanosis and collapse.
In all incidents caused by the action of morphine or levomethadone, morphine antagonists can be used, e.g. B. naloxone hydrochloride.

In the case of circulatory weakness or failure of the peripheral circulation, additional circulatory support therapy with peripherally effective agents should be undertaken.

Incompatibilities
Not specified.

Special precautions for disposal of any unused product or waste materials, if necessary

The drug is subject to the provisions of the Narcotics Act.

Unused narcotics must be destroyed in such a way that even partial recovery of the narcotics is impossible.

Forms of trade

100 ml solution for injection

was standing

April 2010